Corcept Therapeutics Incorporated

NASDAQ:CORT

Biotechnology

Healthcare
$67.79 -2.34%

-$1.96 today

Market cap
$7.42B
Beta
0.50
P/E (TTM)
178.2
EPS (TTM)
$0.46
52W Low $28.66High $91.00

Volume 0.74M

Average 1.41M

CORT Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Corcept Therapeutics IncorporatedNASDAQ: CORT

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development dips below year-ago levels

Q2 FY2026 research & development of $53.89M fell 10.9% year over year, behind the +1.2% change in trailing-twelve-month research & development. Sequentially, it fell 18.7% from the prior quarter. Over 3 fiscal years it compounded at +24.8% a year.

Context

  • Research & development amounted to 33.5% of revenue in FY2025, down 3.1 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -10.9% toward the trailing-twelve-month pace of +1.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$53.89M-18.7% QoQ
Last fiscal yearDec 2025
$254.91M+3.2% YoY
LTMJun 2026
$253.86M+1.2% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-10.9%——
1 year+3.2%——
3-year CAGR+24.8%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
254.91M USD
Year-over-year change
+3.2%
4-year CAGR
+22.3%

Research & Development vs competitors

How CORT compares with its peers on the latest reported figures

  • CORT's LTM Jun 2026 research & development of $253.86M is the highest of the 3 companies compared; the peer median is $58.98M.
  • Its year-over-year change of +1.2% is the 2nd highest of 3, against a peer median of -14.4%.
  • Research & development amounts to 30.6% of revenue for CORT.
CORT Competitors Peer median
Research & Development for CORT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CORTCorcept Therapeutics IncorporatedLTM Jun 2026$253.86M +1.2%+24.8%30.6%
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$101.27M +35.7%+54.7%—
SPRBSpruce Biosciences, Inc.LTM Mar 2026$16.69M -64.4%-17.8%—
Peer median (excluding CORT) $58.98M-14.4%+18.4%—

Competitors are the stored peer set for CORT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue365.98M401.86M482.38M675.04M761.41M
Cost of Revenue5.28M5.39M6.48M10.88M12.98M
Gross Profit360.7M396.47M475.89M664.16M748.43M
Gross Margin98.6%98.7%98.7%98.4%98.3%
Research & Development113.86M130.99M184.35M246.89M254.91M
Selling, General & Admin122.36M152.85M184.26M280.32M448.73M
Operating Expenses236.22M283.84M368.61M527.21M703.63M
Depreciation & Amortization3.07M3.45M2.36M1.34M1.89M
EBITDA127.95M119.64M126.92M162.83M68.35M
EBITDA Margin35.0%29.8%26.3%24.1%9.0%
Operating Income124.48M112.63M107.28M136.95M44.8M
Operating Margin34.0%28.0%22.2%20.3%5.9%
Interest Income529K3.56M17.28M24.54M21.67M
Interest Expense00000
Other Income / Expenses529K3.56M17.28M24.54M21.67M
Income Before Tax125.01M116.19M124.56M161.49M66.46M
Pre-Tax Margin34.2%28.9%25.8%23.9%8.7%
Income Tax Expense12.49M14.77M18.42M20.28M(33.19M)
Net Income112.51M101.42M106.14M139.73M99.65M
Net Margin30.7%25.2%22.0%20.7%13.1%
EPS (Basic)0.970.951.021.350.95
EPS (Diluted)0.890.870.941.230.82
Weighted Avg Shares115.65M106.79M103.56M103.23M103.86M
Weighted Avg Shares (Diluted)125.96M115.97M111.74M113.48M119.99M

Corcept Therapeutics Incorporated

NASDAQ:CORT

Intrinsic Alpha fair value

Locked

Current Price

$67.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.